



(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 35/00* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/EP2018/065239

(22) International Filing Date:
08 June 2018 (08.06.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:


62/517,150	08 June 2017 (08.06.2017)	US
62/517,149	08 June 2017 (08.06.2017)	US
62/517,734	09 June 2017 (09.06.2017)	US
62/517,740	09 June 2017 (09.06.2017)	US
62/517,165	09 June 2017 (09.06.2017)	US
62/517,164	09 June 2017 (09.06.2017)	US
62/517,745	09 June 2017 (09.06.2017)	US
62/517,753	09 June 2017 (09.06.2017)	US
62/582,681	07 November 2017 (07.11.2017)	US
62/582,666	07 November 2017 (07.11.2017)	US
62/582,653	07 November 2017 (07.11.2017)	US
62/582,676	07 November 2017 (07.11.2017)	US

(71) Applicant: **TUSK THERAPEUTICS LTD** [GB/GB];
Stevenage Bioscience Catalyst, Accelerator Building, Gun-
nells Wood Road, Stevenage Hertfordshire SG1 2FX (GB).

(72) Inventors: **MERCHERS, Pascal**; c/o Tusk Therapeu-
tics Limited, Stevenage Bioscience Catalyst, Gunnells
Wood Road, Stevenage Hertfordshire SG1 2FX (GB).
GOUBIER, Anne; c/o Tusk Therapeutics Limited, Steve-
nage Bioscience Catalyst, Gunnells Wood Road, Steve-
nage Hertfordshire SG1 2FX (GB). **MOULDER, Kevin**;
c/o Tusk Therapeutics Limited, Stevenage Bioscience
Catalyst, Gunnells Wood Road, Stevenage Hertfordshire
SG1 2FX (GB). **EISSLER, Nina**; c/o Tusk Therapeutics
Limited, Stevenage Bioscience Catalyst, Gunnells Wood
Road, Stevenage Hertfordshire SG1 2FX (GB). **SALIMU,**
Josephine; c/o Tusk Therapeutics Limited, Stevenage Bio-
science Catalyst, Gunnells Wood Road, Stevenage Hert-
fordshire SG1 2FX (GB). **FILOSTO, Simone**; c/o Tusk
Therapeutics Limited, Stevenage Bioscience Catalyst, Gun-
nells Wood Road, Stevenage Hertfordshire SG1 2FX (GB).
GOYENECHEA, Beatriz; c/o Tusk Therapeutics Limit-
ed, Stevenage Bioscience Catalyst, Gunnells Wood Road,
Stevenage Hertfordshire SG1 2FX (GB). **BARUAH, He-**
manta; c/o Adimab, LLC, 7 Lucent Drive, Lebanon, New
Hampshire 03766 (US). **PRINZ, Bianka**; c/o Adimab,

(54) Title: CD38 MODULATING ANTIBODY

FIGURE 6



(57) Abstract: The present disclosure provides antibody se-
quences found in antibodies that bind to human CD38. In par-
ticular, the present disclosure provides sequences of anti-human
CD38 antibodies. Antibodies and antigen-binding portions there-
of including such sequences present features compatible with
pharmaceutical manufacturing and development can be provid-
ed as fully human antibodies (e.g., fully human monoclonal an-
tibodies or antigen-binding fragments) that can be useful for med-
ical methods and compositions, in particular for treating cancer.

LLC, 7 Lucent Drive, Lebanon, New Hampshire 03766 (US).

(74) **Agent: LEONARD, Thomas Charles** et al.; Kilburn & Strode LLP, Lacon London, 84 Theobalds Road, London London WC1X 8NL (GB).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))